etomoxir has been researched along with ranolazine in 10 studies
| Studies (etomoxir) | Trials (etomoxir) | Recent Studies (post-2010) (etomoxir) | Studies (ranolazine) | Trials (ranolazine) | Recent Studies (post-2010) (ranolazine) |
|---|---|---|---|---|---|
| 260 | 8 | 93 | 799 | 104 | 498 |
| Protein | Taxonomy | etomoxir (IC50) | ranolazine (IC50) |
|---|---|---|---|
| Sodium channel protein type 5 subunit alpha | Homo sapiens (human) | 6.85 | |
| Voltage-gated sodium channel Nav1.5 cardiac isoform | Canis lupus familiaris (dog) | 6.9 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (60.00) | 29.6817 |
| 2010's | 3 (30.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Maisch, B; Rupp, H; Zarain-Herzberg, A | 1 |
| Frenneaux, M; Horowitz, J; Lee, L | 1 |
| Taegtmeyer, H | 1 |
| Inglis, S; Stewart, S | 1 |
| Abozguia, K; Clarke, K; Frenneaux, M; Lee, L | 1 |
| Marazzi, G; Rosano, GM; Volterrani, M | 1 |
| Mellana, WM; Mohan, D; Palaniswamy, C; Selvaraj, DR | 1 |
| Heggermont, WA; Heymans, S; Papageorgiou, AP; van Bilsen, M | 1 |
| Devarakonda, T; Fang, X; Ma, Y; Salloum, FN; Spiegel, S; Wang, W; Wang, XY; Zhou, H | 1 |
6 review(s) available for etomoxir and ranolazine
| Article | Year |
|---|---|
The use of partial fatty acid oxidation inhibitors for metabolic therapy of angina pectoris and heart failure.
Topics: Acetanilides; Angina Pectoris; Animals; Calcium; Cardiovascular Agents; Clinical Trials as Topic; Enzyme Inhibitors; Epoxy Compounds; Fatty Acids; Gene Expression; Glucose; Heart Failure; Humans; Hypoglycemic Agents; Methylhydrazines; Myocytes, Cardiac; Oxidation-Reduction; Piperazines; Ranolazine; Rats; Rats, Wistar; Sarcoplasmic Reticulum; Trimetazidine; Up-Regulation; Vasodilator Agents | 2002 |
Metabolic manipulation in ischaemic heart disease, a novel approach to treatment.
Topics: Acetanilides; Adrenergic beta-Antagonists; Angina Pectoris; Cardiovascular Agents; Drug Therapy, Combination; Enzyme Inhibitors; Epoxy Compounds; Glucose; Humans; Hypoglycemic Agents; Insulin; Myocardial Ischemia; Myocardium; Perhexiline; Piperazines; Potassium; Ranolazine; Trimetazidine | 2004 |
Metabolic therapeutics in angina pectoris: history revisited with perhexiline.
Topics: Acetanilides; Angina Pectoris; Calcium Channel Blockers; Cardiovascular Agents; Carnitine O-Palmitoyltransferase; Drug Monitoring; Epoxy Compounds; Fatty Acids; Half-Life; Humans; Metabolic Clearance Rate; Nurse's Role; Nursing Assessment; Patient Education as Topic; Patient Selection; Perhexiline; Piperazines; Randomized Controlled Trials as Topic; Ranolazine; Treatment Outcome; Trimetazidine; Vasodilator Agents | 2006 |
Modification of myocardial substrate use as a therapy for heart failure.
Topics: Acetanilides; Adrenergic beta-Antagonists; Animals; Cardiac Output, Low; Cardiovascular Agents; Energy Metabolism; Epoxy Compounds; Fatty Acids, Nonesterified; Glycine; Heart; Humans; Myocardium; Oxygen; Perhexiline; Piperazines; Ranolazine; Trimetazidine | 2006 |
Metabolic modulation: a new therapeutic target in treatment of heart failure.
Topics: Acetanilides; Carnitine O-Palmitoyltransferase; Enzyme Inhibitors; Epoxy Compounds; Fatty Acids; Glucose; Heart Failure; Humans; Mitochondria, Heart; Myocytes, Cardiac; Perhexiline; Piperazines; Ranolazine; Trimetazidine; Vasodilator Agents | 2011 |
Metabolic support for the heart: complementary therapy for heart failure?
Topics: Acetyl-CoA C-Acyltransferase; Cardiovascular Agents; Carnitine; Carnitine O-Palmitoyltransferase; Dichloroacetic Acid; Energy Metabolism; Enzyme Inhibitors; Epoxy Compounds; Fatty Acids; Glucose; Heart Failure; Humans; Myocardium; Myocytes, Cardiac; Oxidation-Reduction; Perhexiline; Ranolazine; Stroke Volume; Trimetazidine | 2016 |
4 other study(ies) available for etomoxir and ranolazine
| Article | Year |
|---|---|
Cardiac metabolism as a target for the treatment of heart failure.
Topics: Acetanilides; Animals; Dogs; Energy Metabolism; Epoxy Compounds; Fatty Acids; Forecasting; Glucagon; Glucagon-Like Peptide 1; Glucose; Heart Failure; Humans; Insulin Resistance; Myocardium; Peptide Fragments; Piperazines; Protein Precursors; Ranolazine; Recombinant Proteins | 2004 |
Metabolic agents in the management of diabetic coronary patients: a new era.
Topics: Acetanilides; Citric Acid Cycle; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dichloroacetic Acid; Enzyme Inhibitors; Epoxy Compounds; Humans; Insulin Resistance; Perhexiline; Piperazines; Ranolazine; Trimetazidine; Vasodilator Agents | 2008 |
Shedding Light on Fat Dependence in AML.
Topics: Acetyl-CoA Carboxylase; Adenylate Kinase; Epoxy Compounds; Humans; Hypoxia-Inducible Factor-Proline Dioxygenases; Leukemia, Myeloid, Acute; Lipid Metabolism; Oxidation-Reduction; Phosphorylation; Ranolazine; Tumor Cells, Cultured | 2016 |
Functional analysis of molecular and pharmacological modulators of mitochondrial fatty acid oxidation.
Topics: Animals; Energy Metabolism; Epoxy Compounds; Fatty Acids; Female; Glycine; Humans; MCF-7 Cells; Mice; Mice, Inbred C57BL; Mitochondria; Oxidation-Reduction; PPAR alpha; Ranolazine; Trimetazidine | 2020 |